Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. Company
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of ophthalmia and hepatitis. Net sales break down by category of products as follows:

- chemical medicine products and biopharmaceutical drugs (97.4%);

- other (2.6%).

Number of employees : 24 108 people.
Sales per Business
20192020Delta
Modern Chinese Medicines and Chemical Medicines26 842.1097.7%25 944.0097.6% -3.35%
Others637.262.3%628.242.4% -1.42%
HKD in Million
Sales per region
20192020Delta
China27 479.40100%26 572.20100% -3.3%
HKD in Million
Managers
Name Title Age Since
Yi Li Chief Executive Officer & Executive Director 59 2020
Hsuan Tse General Manager-Information Management 50 2003
Wei Nong Ye General Manager-Research & Development 57 2002
Mao Li Chief Medical Officer - 2021
Zheng Fei Lu, Dr. Independent Non-Executive Director 57 2007
Da Kui Li Independent Non-Executive Director 76 2004
Hong Lu Independent Non-Executive Director 51 2015
Lu Fu Zhang Independent Non-Executive Director 64 2015
Kwok Tung Li, Dr. Independent Non-Executive Director 65 2020
Hsin Tse Executive Director & Vice President 50 2013
Members of the board
Name Title Age Since
Y Y Tse Chairman 28 2015
Ping Tse Senior Vice Chairman 69 2020
Hsin Tse Executive Director & Vice President 50 2013
Cheung Ling Cheng Vice Chairman 57 2017
Zheng Fei Lu, Dr. Independent Non-Executive Director 57 2007
Da Kui Li Independent Non-Executive Director 76 2004
Ming Qin Li Executive Director & Vice President 62 2015
Zhou Shan Tian Executive Director 56 1997
Shan Chun Wang Executive Director 52 2015
Hong Lu Independent Non-Executive Director 51 2015
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 18,849,394,230 9,844,153,595 52.2% 0 0.0% 52.2%
Shareholders
NameEquities%
S Y Tse 4,050,000,000 21.5%
Y Y Tse 2,279,254,761 12.1%
Ping Tse 1,621,403,124 8.60%
GIC Pte Ltd. (Investment Management) 941,876,116 5.00%
Cheung Ling Cheng 880,034,750 4.67%
The Vanguard Group, Inc. 306,051,986 1.62%
BlackRock Fund Advisors 206,168,500 1.09%
Hsin Tse 174,247,000 0.92%
E Fund Management Co., Ltd. 161,993,750 0.86%
First Sentier Investors (Hong Kong) Ltd. 149,723,500 0.79%
Holdings
NameEquities%Valuation
KAROLINSKA DEVELOPMENT AB (PUBL) (KDEV) 75,727,285 43.5% 32,373,414 USD
Markets and indexes
- Primary Listing
- Hang Seng /
Stock Exchange Codes
- Bloomberg Code :  1177:HK
- Reuters Code :  1177.HK
- Datastream Code :  
Company contact information
Sino Biopharmaceutical Limited
Rm 4109, Office Tower, Convention Plaza, 1 Harbour Road
HK- Wanchai, Hong Kong

Phone : +852 2802 9886
Fax : +852 2880 0847
web site : http://www.sinobiopharm.com/
Brand Portfolio
In partnership withAllbrands.markets
More brands of Sino Biopharmaceutical Limited
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-20.40%14 624
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952
MERCK & CO., INC.-0.89%205 219
ABBVIE INC.1.18%191 579
NOVARTIS AG-7.09%188 985
ASTRAZENECA PLC19.72%187 751
BRISTOL-MYERS SQUIBB COMPANY-6.38%129 038
SANOFI7.28%123 403
AMGEN INC.-8.81%119 056
GLAXOSMITHKLINE PLC4.93%97 422
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-27.89%57 118
BAYER AG0.04%55 110
JIANGSU HENGRUI MEDICINE CO., LTD.-44.47%51 415
DAIICHI SANKYO COMPANY, LIMITED-21.92%46 314
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.56%44 688
ASTELLAS PHARMA INC.22.37%31 643